689 related articles for article (PubMed ID: 30844611)
21. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
[TBL] [Abstract][Full Text] [Related]
22. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis.
Vollmer TL; Cohen JA; Alvarez E; Nair KV; Boster A; Katz J; Pardo G; Pei J; Raut P; Merchant S; MacLean E; Pradhan A; Moss B
Mult Scler Relat Disord; 2020 Nov; 46():102454. PubMed ID: 33045496
[TBL] [Abstract][Full Text] [Related]
23. Ocrelizumab: its efficacy and safety in multiple sclerosis.
Juanatey A; Blanco-Garcia L; Tellez N
Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
[TBL] [Abstract][Full Text] [Related]
24. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
Hauser SL; Kappos L; Arnold DL; Bar-Or A; Brochet B; Naismith RT; Traboulsee A; Wolinsky JS; Belachew S; Koendgen H; Levesque V; Manfrini M; Model F; Hubeaux S; Mehta L; Montalban X
Neurology; 2020 Sep; 95(13):e1854-e1867. PubMed ID: 32690791
[TBL] [Abstract][Full Text] [Related]
25. Ocrelizumab: a new milestone in multiple sclerosis therapy.
Mulero P; Midaglia L; Montalban X
Ther Adv Neurol Disord; 2018; 11():1756286418773025. PubMed ID: 29774057
[TBL] [Abstract][Full Text] [Related]
26. Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS.
Hartung HP;
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503093
[TBL] [Abstract][Full Text] [Related]
27. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
Fox EJ; Markowitz C; Applebee A; Montalban X; Wolinsky JS; Belachew S; Fiore D; Pei J; Musch B; Giovannoni G
Mult Scler; 2018 Dec; 24(14):1862-1870. PubMed ID: 30415593
[TBL] [Abstract][Full Text] [Related]
28. Ocrelizumab: A Review in Multiple Sclerosis.
Lamb YN
Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
[TBL] [Abstract][Full Text] [Related]
29. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.
Wolinsky JS; Montalban X; Hauser SL; Giovannoni G; Vermersch P; Bernasconi C; Deol-Bhullar G; Garren H; Chin P; Belachew S; Kappos L
Ann Neurol; 2018 Oct; 84(4):527-536. PubMed ID: 30155979
[TBL] [Abstract][Full Text] [Related]
31. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Genovese MC; Kaine JL; Lowenstein MB; Del Giudice J; Baldassare A; Schechtman J; Fudman E; Kohen M; Gujrathi S; Trapp RG; Sweiss NJ; Spaniolo G; Dummer W;
Arthritis Rheum; 2008 Sep; 58(9):2652-61. PubMed ID: 18759293
[TBL] [Abstract][Full Text] [Related]
32. Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials.
Krishnan AP; Song Z; Clayton D; Gaetano L; Jia X; de Crespigny A; Bengtsson T; Carano RAD
Radiology; 2022 Mar; 302(3):662-673. PubMed ID: 34904871
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.
Mysler EF; Spindler AJ; Guzman R; Bijl M; Jayne D; Furie RA; Houssiau FA; Drappa J; Close D; Maciuca R; Rao K; Shahdad S; Brunetta P
Arthritis Rheum; 2013 Sep; 65(9):2368-79. PubMed ID: 23740801
[TBL] [Abstract][Full Text] [Related]
34. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
36. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis.
Barrera B; Simpson H; Engebretson E; Sillau S; Valdez B; Parra-González J; Winger RC; Epperson LA; Banks A; Pierce K; Spotts M; O'Gean K; Alvarez E; Gross R; Piquet AL; Schreiner T; Corboy JR; Pei J; Vollmer TL; Nair KV
Ann Clin Transl Neurol; 2023 Apr; 10(4):579-588. PubMed ID: 36811392
[TBL] [Abstract][Full Text] [Related]
37. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.
Sorensen PS; Blinkenberg M
Ther Adv Neurol Disord; 2016 Jan; 9(1):44-52. PubMed ID: 26788130
[TBL] [Abstract][Full Text] [Related]
38. Ocrelizumab initiation in patients with MS: A multicenter observational study.
Ellwardt E; Rolfes L; Klein J; Pape K; Ruck T; Wiendl H; Schroeter M; Zipp F; Meuth SG; Warnke C; Bittner S
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32273482
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.
Wininger SJ; Miller H; Minkowitz HS; Royal MA; Ang RY; Breitmeyer JB; Singla NK
Clin Ther; 2010 Dec; 32(14):2348-69. PubMed ID: 21353105
[TBL] [Abstract][Full Text] [Related]
40. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
Fernandez-Diaz E; Perez-Vicente JA; Villaverde-Gonzalez R; Berenguer-Ruiz L; Candeliere Merlicco A; Martinez-Navarro ML; Gracia Gil J; Romero-Sanchez CM; Alfaro-Saez A; Diaz I; Gimenez-Martinez J; Mendez-Miralles MA; Millan-Pascual J; Jimenez-Pancho J; Mola S; Sempere AP
Ann Clin Transl Neurol; 2021 Feb; 8(2):385-394. PubMed ID: 33369288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
